; ·	us	Approv	PTO/SB/21 (09-04) yed for use through 07/31/2008, OMB 0851-0031 ark Office; U.S. DEPARTMENT OF COMMERCE
Under the Passenwork Reduction Act of 129  TRANSMITTAL			no umiesa il displays a valid QM9 commi number.
FORM	First Named Inventor Art Unit	James M. Wilson 1635	CERTIFIC 0 4 200
(to be used for all correspondence after inition  Total Number of Pages in This Submission	Examiner Name  Attorney Docket Number	Whiteman, Brian	
	ENCLOSURES (Check all	i that apply)	
Fee Transmittal Form  Fee Attached  Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request  Information Disclosure Statement  Certified Copy of Priority Document(s)  Reply to Missing Parts/ Incomplete Application Reply to Missing Parts  under 37 CFR 1.52 or 1.53	Drawing(s)  Licensing-related Papers  Petition Petition to Convert to a Provisional Application Power of Attorney, Revocatic Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on C  Remarks Customer No. 00270	Address	After Allowance Communication to TC  Appeal Communication to Board of Appeals and Interferences  Appeal Communication to TC (Appeal Notice, Brief, Repty Brief)  Proprietary Information  Status Letter  Other Enclosure(s) (please identify below):
SIGNA	ATURE OF APPLICANT, ATTO	RNEY, OR A	GENT
imm Name Howson and Howson Signature Cashe 4	and earl		
Printed name Cethy A. Kodeff	10		,
2-4-2005		Reg. No. 33,9	80
hereby certify that this correspondence is sufficient postage as first class mail in an e	CERTIFICATE OF TRANSMISS being facsimile transmitted to the USPT invelope addressed to: Commissioner for	O or deposited w	ith the United States Postal Service with
the date shown below: Signature	TAS:	1	
Typed or printed name Rubes	F Ja Duminion took		Date 7 - 4 - 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, cell 1-800-PTO-9199 and select option 2.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.: 09/757,673

Confirmation No. 8771

Applicant: James M. Wilson, et al.

Filed: January 10, 2001

TC/A.U.: 1635

Examiner: Whiteman, Brian A.

Docket No.: GNVPN.019B1USA

Customer No.: 00270

## CERTIFICATE OF TRANSMISSION OR MAILING UNDER 37 C.F.R. 1.8

I certify that this paper is being facsimile transmitted, or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed, to the Commissioner for Patents, the United States Patent and Trademark Office, on the date shown below.

Signed Roll J. Dumin Printed Name Roll J. Dumin Dated: France 4, 2005

Title: METHOD FOR RECOMBINANT ADENO-ASSOCIATED VIRUS-DIRECTED GENE THERAPY

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## RESPONSE TO NOTICE OF NON-RESPONSIVE AMENDMENT

Sir:

This paper is in timely response to a Notice of Non-Responsive Amendment, dated January 28, 2005. In response, Applicants are submitting only the corrected section of the non-responsive amendment, i.e., the entire "Amendments to the Claims" section is being resubmitted.

Kindly amend the application as follows.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 8 of this paper.